When Mersana Therapeutics Inc.'s Phase I program for its lead candidate XMT-1522, an antibody drug conjugate (ADC) targeting HER2, was put on partial clinical hold in July following a patient death, the company acted quickly to change the study protocols to regulator's satisfaction. (Also see "Mersana's ADC Technology Faces A Setback With Partial Clinical Trial Hold " - Scrip, 19 July, 2018.)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?